Men's Health Network And Auxilium Pharmaceuticals, Inc. Mark Men's Health Month With "Ask About The Curve™" Collaboration To

  Men's Health Network And Auxilium Pharmaceuticals, Inc. Mark Men's Health
     Month With "Ask About The Curve™" Collaboration To Encourage Greater
                     Understanding Of Peyronie's Disease

National Survey Reveals Gaps in Perceptions and Realities of Living with
Peyronie's Disease, as Experienced by Both Men and Their Partners

PR Newswire

WASHINGTON, and CHESTERBROOK, Pa., June 11, 2013

WASHINGTON, and CHESTERBROOK, Pa., June 11, 2013 /PRNewswire/ --Men's Health
Network ("MHN") and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty
biopharmaceutical company, have announced the launch of a new health awareness
program called "Ask About the Curve" to provide information about Peyronie's
disease (PD) and to help empower men to have meaningful discussions about
their condition with their partner and their healthcare provider. PD is a
condition, perhaps related to injury or inherited predispositions, in which
collagen scar tissue often develops under the skin of the penis. The scar
tissue, known as a Peyronie's plaque, can feel like a bump and cause the penis
to curve or bend when erect. This curvature deformity of the penis can be a
devastating disorder that can impact sexual intercourse, erections and
erection appearance, and can cause affected men to feel bothered, distressed,
or embarrassed.


As Juneis Men's Health Month, the results of a national opinion survey,
supported by Auxilium, of 550 men with PD and their partners show the greater
need for understanding of the condition from both perspectives. Key findings
of the survey reveal:

  oMen and their partners experience personal distress related to Peyronie's
    disease that for the most part does not appear to subside over time. When
    asked to consider whether personal distress related to PD has changed from
    diagnosis to today, 88 percent of men indicated that it has remained the
    same or worsened. 78 percent of partners indicated that their personal
    distress has remained the same or worsened.
  oThere is a disparity between men and their partners when asked whether
    "functional" versus "psychological" aspects of Peyronie's disease cause
    the most bother.  When asked which aspects of PD bothered them the most,
    men with PD selected functional aspects, such as curvature of the erect
    penis and performance anxiety, while partners selected psychological
    effects associated with PD, such as avoidance of intimacy and lowered
  oPeyronie's disease is characterized variously among men with PD and their
    partners, but the majority rank-order three terms most frequently.  Of
    both the men with PD and partners polled, the three most common terms used
    to describe PD were: "embarrassment," "deformity" and "disease."
  oMen with Peyronie's disease may bear the burden alone, despite their
    relationships with a partner and with a doctor.  42 percent of men with PD
    responded that they have not talked to their partner about their condition
    and 22 percent have not spoken with anybody about their condition.

"Despite the sensitive nature of Peyronie's disease, MHN is approached more
and more frequently about curved erections and the impact it has on men and
their partners," explained Ana Fadich, Vice President at MHN. "This made us
realize that men and their partners are looking for valuable information about
Peyronie's disease. 'Ask About the Curve' is an excellent resource."

Ask About the Curve is a program developed to help men start the conversation
about Peyronie's. There are a number of resources available at Visitors can learn more about Peyronie's
disease and its impact, hear from experts about how to deal with the condition
and get advice on talking about Peyronie's with a partner and their healthcare

"Auxilium is truly excited to be collaborating with such a well-known leader
in the field of men's health to help men and their partners understand the
condition and ultimately have meaningful conversations with their partners and
their healthcare providers ," added Adrian Adams, President and CEO of

For men with Peyronie's disease, the impact goes beyond the physical symptoms
and may include sexual, psychological, and social effects. Every year, it is
estimated at least 65,000 men are diagnosed with Peyronie's disease in the
U.S., although the actual incidence may be potentially underdiagnosed because
men are embarrassed to seek help for their condition.

About Peyronie's Disease
PD can affect men both physically and psychosocially. The disorder can result
in varying degrees of penile curvature deformity, disease bother, sexual
dysfunction, emotional distress, loss of self-esteem and depression. PD often
involves the development of collagen plaque, or scar tissue, on the shaft of
the penis that may harden and reduce flexibility, thus occasionally causing
pain and bending or arcing of the penis during erection. In addition to
difficulty with sexual intercourse, PD is commonly associated with emotional
distress, loss of self-esteem, disease bother and depression. PD is a
heterogeneous disease with an initial inflammatory component. This
inflammatory phase is poorly understood with a somewhat variable disease
course and occasional spontaneous resolutions of not greater than 13%^1.
After 12-18 months of disease, the disease is reported to often develop into
a more chronic, stable phase^1. The estimated prevalence in adult men of PD
has been reported to be approximately 5%^2; however the disease is thought to
be underdiagnosed and undertreated^1. Based on U.S. historical medical claims
data, it is estimated that between 65,000 and 120,000 PD patients are
diagnosed every year, but only 5,000 to 6,500 PD patients are treated with
injectables or surgery annually^3.

(1) L.A. Levine Peyronie's Disease: A Guide to Clinical Management. Humana
Press: 10-17, 2007.
(2) Bella A. Peyronie's Disease J Sex Med 2007;4:1527–1538
(3) SDI and data on file, Auxilium

About Men's Health Network
Men's Health Network, formed in 1992, is based in Washington, D.C. and led the
efforts to sign National Men's Health Week into law. Men's Health Network
works with places of worship, workplaces, policymakers, government agencies,
fatherhood initiatives, and health organizations across the country to raise
awareness of men's health.

Men's Health Network (MHN) is a non-profit organization whose mission is to
reach men, boys and their families where they live, work, play and pray with
health prevention messages and tools, screening programs, educational
materials, advocacy opportunities and patient navigation. With a network of
chapters, affiliates, and health partners, MHN has a presence in every state
and over 30 countries. Learn more about MHN at and
follow MHN on Twitter @MensHlthNetwork.

About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a
focus on developing and marketing products to predominantly specialist
audiences. Auxilium markets Testim® 1% (testosterone gel) for the topical
treatment of hypogonadism in the U.S., XIAFLEX® (collagenase clostridium
histolyticum (CCH)) for the treatment of adult Dupuytren's contracture
patients with a palpable cord in the U.S., and distributes XIAPEX® (the EU
tradename for CCH) in the European Union through Pfizer Inc. under a
transition services agreement until the applicable marketing authorizations
are fully transferred to Auxilium. GlaxoSmithKline LLC co-promotes Testim
with Auxilium in the U.S. Ferring International Center S.A. markets Testim in
certain countries of the EU and Paladin Labs Inc. markets Testim in Canada.
Asahi Kasei Pharma Corporation has development and commercial rights for
XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development and
commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico.
Auxilium acquired Actient Holdings, Inc. on April 26, 2013 and an array of
men's health products and certain other products, including Testopel® for
testosterone replacement therapy and Edex® for the treatment of erectile
dysfunction. Auxilium has three projects for CCH in clinical development.
Auxilium also has rights to pursue additional indications for CCH. For
additional information, visit

ACT OF 1995
This release contains "forward-looking-statements" within the meaning of The
Private Securities Litigation Reform Act of 1995, including statements
regarding the Company's intention to work with the Men's Health Network, and
the prevalence of Peyronie's disease. All statements other than statements of
historical facts contained in this release, including but not limited to,
statements regarding future expectations, plans and prospects for the Company,
statements regarding forward-looking financial information and other
statements containing the words "believe," "appears," "may," "could," "will,"
"estimate," "continue," "anticipate," "intend," "should," "plan," "expect,"
and similar expressions, as they relate to the Company, constitute
forward-looking statements. Actual results may differ materially from those
reflected in these forward-looking statements due to various factors,
including further evaluation of clinical data, results of clinical trials, the
performance of third-party service providers, decisions by regulatory
authorities regarding whether or when to proceed to the next phase of clinical
trials, general financial, economic, regulatory and political conditions
affecting the biotechnology and pharmaceutical industries and those discussed
in the Company's Annual Report on Form 10-K for the year ended December 31,
2012 under the heading "Risk Factors," and in other public filings with the
Securities and Exchange Commission (the "SEC"), including, without limitation,
as such Form 10-K was updated in Item 8.01 of the Current Report on Form 8-K
filed on April 29, 2013, which are on file with the SEC and may be accessed
electronically by means of the SEC's home page on the Internet at or by means of the Company's home page on the Internet at under the heading "For Investors -- SEC Filings."
There may be additional risks that the Company does not presently know or that
the Company currently believes are immaterial which could also cause actual
results to differ from those contained in forward-looking statements. Given
these risks and uncertainties, any or all of the forward-looking statements
contained in this release may prove to be incorrect. Therefore, you should not
rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide the Company's expectations,
plans or forecasts of future events and views as of the date of this release.
The Company anticipates that subsequent events and developments will cause the
Company's assessments to change. However, while the Company may elect to
update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These forward-looking
statements should not be relied upon as representing the Company's assessments
as of any date subsequent to the date of this release.

James E. Fickenscher/CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900

William Q. Sargent Jr./ VP IR
Auxilium Pharmaceuticals, Inc.
(484) 321-5900

Ana Fadich
Men's Health Network
(202) 543-6461

SOURCE Auxilium Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.